"Cell Line, Tumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell line derived from cultured tumor cells.
| Descriptor ID |
D045744
|
| MeSH Number(s) |
A11.251.210.190 A11.251.860.180
|
| Concept/Terms |
Cell Line, Tumor- Cell Line, Tumor
- Cell Lines, Tumor
- Line, Tumor Cell
- Lines, Tumor Cell
- Tumor Cell Lines
- Tumor Cell Line
|
Below are MeSH descriptors whose meaning is more general than "Cell Line, Tumor".
Below are MeSH descriptors whose meaning is more specific than "Cell Line, Tumor".
This graph shows the total number of publications written about "Cell Line, Tumor" by people in this website by year, and whether "Cell Line, Tumor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 20 | 20 |
| 2004 | 0 | 68 | 68 |
| 2005 | 0 | 71 | 71 |
| 2006 | 1 | 58 | 59 |
| 2007 | 0 | 69 | 69 |
| 2008 | 1 | 79 | 80 |
| 2009 | 2 | 111 | 113 |
| 2010 | 0 | 91 | 91 |
| 2011 | 0 | 118 | 118 |
| 2012 | 1 | 87 | 88 |
| 2013 | 2 | 109 | 111 |
| 2014 | 0 | 118 | 118 |
| 2015 | 0 | 128 | 128 |
| 2016 | 0 | 129 | 129 |
| 2017 | 0 | 90 | 90 |
| 2018 | 0 | 134 | 134 |
| 2019 | 0 | 111 | 111 |
| 2020 | 0 | 114 | 114 |
| 2021 | 0 | 96 | 96 |
| 2022 | 0 | 35 | 35 |
| 2023 | 0 | 47 | 47 |
| 2024 | 0 | 84 | 84 |
| 2025 | 0 | 11 | 11 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cell Line, Tumor" by people in Profiles.
-
MAGE-A4 induces non-small cell lung cancer and tumor-promoting plasma cell accumulation. Sci Adv. 2025 Feb 14; 11(7):eads4227.
-
Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models. Blood Adv. 2025 Feb 11; 9(3):473-487.
-
Biguanides antithetically regulate tumor properties by the dose-dependent mitochondrial reprogramming-driven c-Src pathway. Cell Rep Med. 2025 Feb 18; 6(2):101941.
-
Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells. Mol Cancer Res. 2025 02 06; 23(2):128-142.
-
Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood. 2025 Feb 06; 145(6):612-624.
-
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clin Cancer Res. 2025 Feb 03; 31(3):573-587.
-
The O-glycosyltransferase C1GALT1 promotes EWSR1::FLI1 expression and is a therapeutic target for Ewing sarcoma. Nat Commun. 2025 Feb 02; 16(1):1267.
-
Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma. Proc Natl Acad Sci U S A. 2025 Jan 28; 122(4):e2319474122.
-
ACE2 Enhances Sensitivity to PD-L1 Blockade by Inhibiting Macrophage-Induced Immunosuppression and Angiogenesis. Cancer Res. 2025 Jan 15; 85(2):299-313.
-
High cellular plasticity state of medulloblastoma local recurrence and distant dissemination. Cell Rep Med. 2025 Jan 21; 6(1):101914.